E-LIB Suche - Ergebnisse für: Shragai, Tamir

1

MM-362 Multiple Myeloma Oligosecretory Relapse: A Cross-Sec..:

Cohen, Inbar ; Vaxman, Iuliana ; Zamir, Itai...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S493 , 2023

Link: https://doi.org/10.1016/..

2

P942: MULTIPLE MYELOMA OLIGOSECRETORY RELAPSE- A CROSS SECT..:

Vaxman, Iuliana ; Zamir, Itai ; Cohen, Inbar...
HemaSphere. 7 (2023) S3 - p. e949198b , 2023

Link: https://doi.org/10.1097/..

3

POSTER: MM-362 Multiple Myeloma Oligosecretory Relapse: A C..:

Cohen, Inbar ; Vaxman, Iuliana ; Zamir, Itai...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S219 , 2023

Link: https://doi.org/10.1016/..

4

Management and outcome of 500 multiple myeloma patients tre..:

Avivi, Irit ; Yekutiel, Naama ; Shragai, Tamir...
Annals of Hematology. 102 (2023) 11 - p. 3075-3081 , 2023

Link: https://doi.org/10.1007/..

5

P560: IMPROVEMENT IN OVERALL AND RELAPSE FREE SURVIVAL OF A..:

Moshe, Yakir ; Levi, Shai ; Neeman, Miri...
HemaSphere. 7 (2023) S3 - p. e75498e6 , 2023

Link: https://doi.org/10.1097/..

6

P571: OUTPATIENT INITIATION OF VENETOCLAX-AZACITIDINE FOR S..:

Gat, Roi ; Neeman, Miri ; Levi, Shai...
HemaSphere. 7 (2023) S3 - p. e4811210 , 2023

Link: https://doi.org/10.1097/..

7

P966: SMOLDERING MULTIPLE MYELOMA (MM) PROGRESSING TO ACTIV..:

Fridberg, Gil ; Shragai, Tamir ; Melamed, Natan...
HemaSphere. 7 (2023) S3 - p. e5068793 , 2023

Link: https://doi.org/10.1097/..

8

Treatment with low‐dose, single‐agent belantamab mafodotin ..:

Avivi, Irit ; Shragai, Tamir ; Luttwak, Efrat..
European Journal of Haematology. , 2023

Link: https://doi.org/10.1111/..

9

P-114: Real-world experience with belantamab mafodotin ther..:

Shragai, Tamir ; Magen, Hila ; Lavi, Noa...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S98 , 2022

Link: https://doi.org/10.1016/..

10

COVID-19 in patients with lymphoproliferative diseases duri..:

Bronstein, Yotam ; Gat, Roi ; Levi, Shai...
Cancer Cell. 40 (2022) 6 - p. 578-580 , 2022

Link: https://doi.org/10.1016/..

11

Real‐world experience with belantamab mafodotin therapy for..:

Shragai, Tamir ; Magen, Hila ; Lavi, Noa...
British Journal of Haematology. 200 (2022) 1 - p. 45-53 , 2022

Link: https://doi.org/10.1111/..

12

Humoral response rate and predictors of response to BNT162b..:

Avivi, Irit ; Balaban, Roi ; Shragai, Tamir...
British Journal of Haematology. 195 (2021) 2 - p. 186-193 , 2021

Link: https://doi.org/10.1111/..

13

Characteristics and outcome of multiple myeloma patients pr..:

Shragai, Tamir ; Gatt, Moshe E. ; Shaulov, Adir...
Leukemia Research. 101 (2021) - p. 106498 , 2021

Link: https://doi.org/10.1016/..

14

Characteristics and outcomes of adults with cytomegalovirus..:

Shragai, Tamir ; Lebel, Eyal ; Deshet, Dana...
British Journal of Haematology. 191 (2020) 5 - p. 863-867 , 2020

Link: https://doi.org/10.1111/..

15

Daratumumab for relapsed AL amyloidosis—When cumulative rea..:

Shragai, Tamir ; Gatt, Moshe ; Lavie, Noa...
European Journal of Haematology. 106 (2020) 2 - p. 184-195 , 2020

Link: https://doi.org/10.1111/..